Contact Us
Drug Search Results
More Filters [+]

Tabalumab

Alternative Names: tabalumab, ly2127399
Latest Update: 2024-12-23
Latest Update Note: News Article

Product Description

Mechanisms of Action: BLyS Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tabalumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Arthritis, Rheumatoid|Lupus Erythematosus, Systemic

Phase 2: Arthritis, Rheumatoid|Multiple Myeloma|Multiple Sclerosis, Relapsing-Remitting|Kidney Failure, Chronic

Phase 1: Multiple Myeloma|Arthritis, Rheumatoid

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
Illuminate-X

P3

Terminated

Lupus Erythematosus, Systemic

2015-10-01

H9S-JE-JDCI

P1

Completed

Multiple Myeloma

2015-02-01

ILLUMINATE-2

P3

Terminated

Lupus Erythematosus, Systemic

2014-12-10

ILLUMINATE-X

P3

Completed

Lupus Erythematosus, Systemic

2014-12-10

Recent News Events

Date

Type

Title

12/23/2024

News Article

 Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

11/14/2024

News Article

 Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

06/14/2024

News Article

 Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

03/28/2024

News Article

 Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

10/16/2023

PubMed

 Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications.

10/09/2023

PubMed

 Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE).

07/23/2023

PubMed

 Efficacy and Safety of New B Cell-Targeted Biologic Agent for the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions